Background: Ingestion of radiopaque markers (ROM) is frequently used to determine
| INTRODUCTION
Affecting approximately 16% of the population with a direct medical cost in excess of $200 million in the USA alone, constipation is common, costly, and one of the most frequent reasons to seek care from a gastroenterologist. Initial symptom-driven treatment options include fiber and/or over-the-counter laxatives before moving to more specialized physiologic testing with the goal of establishing physiologic subtypes including slow transit and pelvic floor dysfunction. 1 Current guidelines recommend the identification and treatment of patients with pelvic floor dysfunction before moving on to an assessment of colonic transit because a substantial proportion of patients with pelvic floor dysfunction have evidence of slowed colonic transit. In practice, colonic transit testing via ingestion of radiopaque markers (ROM) followed by a plain abdominal X-ray is simpler and more palatable to many patients; thus, colonic transit testing is likely more frequently performed in the community prior to anorectal manometry (ARM).
Work from our group previously demonstrated no correlation between the accumulation of markers in the distal colon on X-ray and likelihood of outlet obstruction constipation despite common perception otherwise. 2 Similarly, many clinicians are thought to consider an increasing number of retained markers to correlate with more severe constipation despite the lack of evidence otherwise. We therefore sought to determine the relationship between the number of retained markers on a colonic transit study and a validated measure of constipation symptom severity among patients presenting for evaluation of constipation at a tertiary referral center. Evidence linking symptom scores and retained markers could provide a reasonable means of identifying patients with severe, potentially treatment-refractory disease earlier in their evaluation.
| MATERIALS AND METHODS
We assembled a cross-sectional cohort population of consecutive were excluded if they did not undergo concomitant colonic transit testing (our primary exposure) or were missing information on symptom severity (our primary outcome). All data were assembled by 2 authors (KS and KB).
| Colonic transit assessment
The primary predictor of interest for this study was the number of retained ROM on a day 5 plain abdominal film. We stratified our cohort into patients with markers remaining in the rectosigmoid colon, left colon, and right colon and those with markers localized throughout the colon or no retained markers. This methodology of describing marker location was consistent with a previous study by our group. 2 Further stratification was performed to exclude patients with outlet obstruction as defined by a prolonged balloon expulsion time as part of the ARM protocol. We determined outlet obstruction by means of timed balloon expulsion testing of a 50 mL water-filled balloon inserted in the rectum while the patient is on the commode. 4 We dichotomized this variable into normal (≤2 minutes) or prolonged (>2 minutes) as per established standards. 
Key Points
• Retention ≥20% of retained markers at 5 days defines slow-transit constipation in a radiopaque marker (ROM)
study, but some clinicians use the number of retained markers as a surrogate for disease severity.
• We found no correlation between number of retained ROMs and symptom severity or quality of life in a cohort of patients presenting for evaluation of chronic constipation.
• The results of this study serve as a caution against the overinterpretation of ROM transit testing in chronic constipation.
| Statistical analysis
Continuous variables were summarized using means and standard deviations, while categorical variables were expressed as proportions.
We compared characteristics and responses to survey instruments of patients with no retained markers vs those with retained markers. For the discrete outcomes, univariate comparisons were made using the Fisher's exact test and continuous outcomes were compared using a t test. The Shapiro-Wilk test was used to confirm normality of our data. For our primary outcome, we determined the correlation between number of retained markers and PAC-SYM score and CR-QOL score using Pearson correlation to determine correlation coefficients (R values). We divided the number of retained markers into quartiles and created a multivariable model to assess the relationship between quartile of retained markers and symptom severity (PAC-SYM score)
after adjustment for age, sex, the presence of IBS (By Rome III module), and depression (by HADS). We also performed sensitivity analyses looking at the effect of excluding patients with a Rome III diagnosis of IBS and those with a prolonged balloon expulsion time on ARM.
All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA). Statistical significance was defined by a 2-sided P-value of .05. All authors had access to the study data and reviewed and approved the final manuscript. The study was approved by the Institutional Review Board at Massachusetts General Hospital (Protocol# 2014P001464).
| RESULTS
We identified a total of 326 patients who underwent ARM at (Table 1) . Additionally, there were no significant differences in constipation severity or QOL as assessed by the PAC-SYM (1.83 vs 1.88, P > .05) and CR-QOL (49.6 vs 51.2, P > .05), respectively, between patients with retained markers and those with no retained markers.
For our primary outcome, there was poor correlation between the number of retained markers and symptom severity (R = .09, P = .25) ( Figure 1 ) and QOL (R = .06, P = .46) ( Table 2) . Among the 55 patients with slow-transit constipation defined by ≥5 markers retained on day 5, there were similarly poor correlations between symptom severity (R = .17, P = .21) and QOL (R = .07, P = .60) ( Table 3) .
We performed additional sensitivity analyses excluding patients with IBS (n = 62 without IBS, R = .02, P = .87) and those with outlet obstruction as measured by prolonged balloon expulsion time (n = 92 without outlet obstruction, R = .14, P = .18), which also demonstrated poor correlation between number of retained markers and constipation symptom severity. We also divided the number of retained markers into quartiles and created a multivariable model to assess the impact of quartile of retained markers on symptom severity. After adjustment for age, sex, the presence of IBS, and depression by multiple linear regression analysis, those in highest quartile of retained markers had similar symptom severity scores compared to those in the lowest quartile of retained markers (β = 0.08 (−0.21-0.38), P = .59).
We also assessed the impact of marker location on symptom severity in the 88 patients for whom location data could be determined by radiologist assessment. As above, this was performed in a hierarchical fashion from right to left. There was no significant difference between symptom severity score among patients with markers retained in any region of the colon: right colon (n = 27, 1.76 vs 1.89, P = .41), 
| DISCUSSION
In this cross-sectional study of 159 patients presenting for evaluation of constipation at a tertiary academic center, we found no correlation between the number of retained markers on a colonic transit study and symptom severity or QOL on validated symptom surveys despite controlling for demographics, psychiatric comorbidities, outlet obstruction, and the presence of IBS.
To put these findings in the context of the literature, our observation that symptom severity does not increase with the number of retained ROM on a colonic transit builds upon prior work by Hinton et al. 3 In this original study validating this method of colonic transit analysis, only 2 of the normal subjects had ≥20% of the markers retained at 5 or more days, thus establishing the normal values used today. Our findings are novel in that the number of retained markers beyond the 20% threshold has not-to our knowledge-been evaluated. Previous studies attempting to correlate symptom severity and physiology found that patients with normal colonic transit reported higher symptom severity than those with slow-transit constipation, and even higher symptom severity in patients with visceral hypersensitivity compared to those with slow-transit and pelvic floor dysfunction. 10 
15
Additional limitations include the cross-sectional design of this study, where causation cannot be clearly ascertained, and we cannot exclude the possibility that unmeasured confounders may explain our failure to observe a correlation between symptoms and number of retained markers. Secondly, our patient population was derived from a tertiary referral center, where the population seeking care are more likely to have refractory disease that is not reflective of the consulting population at large. Finally, there is the inherent human error among patients required to abstain from laxatives and simultaneously ensure correct timing between the ingestion of the capsule and the abdominal plain film-leading to potential issues with the reproducibility of a single colonic transit study. 16 Relative strengths of the current study include a robust psychometric and physiologic characterization of this population with the ability to measure symptom severity, QOL, and adjust for psychiatric disease and IBS. Additionally, we were able to account for the presence of pelvic floor dysfunction, which is an important confounder of colonic transit studies in that pelvic floor dysfunction is known to be associated with slow-transit constipation. 17, 18 By failing to demonstrate a correlation between symptom severity and the number of retained markers on a colonic transit study, we suggest that clinicians not overinterpret the meaning of physiologic testing in functional GI disease, where our pathophysiologic understanding fails to account for significant heterogeneity.
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